This amounted to an approximate reduction of almost 50% after 1 month and by 3 months the pain levels had reduced to 25% of their previous levels
and meetings with vendors and IT, quality, leadership, and other staff to assure an understanding of what is reported on Medicare.gov/Care Compare , its impact on public reporting, star reporting, and use by other reporting agencies
What Reclassification Would (and Would Not) Change If BPC-157 is moved to Category 1 after the July 2026 meeting, the regulatory impact is narrower than many online summaries suggest: Scenario Category 2 (current default) Category 1 (post-reclassification) FDA approval No No 503A compounding Not permitted Permitted (pending final rulemaking) 503B outsourcing facilities Separate list (503B bulks list) Separate determination required Commercial drug product Not available Still not available without NDA Research/laboratory use Legal for research Legal for research (unchanged) In plain terms: Category 1 status lets a patient with a valid prescription get BPC-157 prepared by a state-licensed compounding pharmacy
Researchers using nasal spray for TB-500 may need proportionally higher doses compared to BPC-157 to achieve equivalent systemic levels relative to injection administration
Mine is: GHK- CU BPC- 157 & TB500 mix Semax Reta Mots- c Ipamorelin #fitnessmotivation #fitnessmodel #fyp #explore #fitness | Amone Bane
Mid-portion tendinopathy typically responds faster than insertional problems due to easier injection access and slightly better baseline vascularity
